Contrary to startup culture, the best training for biotech leadership is gaining broad, cross-functional experience in a large, structured pharmaceutical company. This foundation provides the necessary depth and breadth to navigate the complexities of leading a smaller, resource-constrained biotech later on.

Kevin Pojasek credits his effectiveness to a deliberate 12-year journey through diverse roles—investing, company creation, research, and clinical operations. This broad experience allows a leader to understand how all parts of the company, from high-level strategy to detailed science, fit together.

Starting in business development at a large firm like Genentech provides a holistic understanding of the entire drug lifecycle—from discovery and regulation to clinical trials and marketing. This "full spectrum" view offers invaluable training for a future CEO.

A former medic explains that hands-on patient care provides an irreplaceable perspective for executives. It grounds strategic decisions in the reality of the patient experience, which is crucial for communicating value to teams and investors and maintaining a patient-first culture.

Derek Adams began in late-stage vaccine manufacturing at Merck before moving to earlier-stage companies. This "reverse" path provides a deep understanding of commercial realities, operational execution, and scale-up challenges that is invaluable for building a capital-efficient startup from the ground up.

Ron Cooper credits his success not to being a "scaling guy" at Bristol-Myers Squibb, but the "fix-it guy." Being deployed to turn around struggling business units across different geographies and therapeutic areas provided the multicultural, problem-solving toolkit essential for navigating the constant challenges of leading a biotech startup.

ACMA's CEO intentionally keeps "liquor store clerk" on his LinkedIn profile to show how early, seemingly unrelated jobs build foundational skills in sales, psychology, and empathy. These formative experiences shape an adult's professional identity and should be valued, not hidden.

Rather than viewing his long tenure at Pfizer as the final destination, Doogan frames it as a crucial learning period. This "apprenticeship" provided invaluable experience with drug development, failure, and industry dynamics, which directly enabled his later success as a biotech founder and executive.

Leonard Mazur's entry into the pharmaceutical industry was not a planned career path but a "random walk." He was drawn to a pharmaceutical sales job ad in the newspaper due to perks like a company car, demonstrating that significant careers can begin with opportunistic choices rather than a grand vision.